Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03476798 · ClinicalTrials.gov registry record · Phase 2
Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium
A Phase 2 study of Endometrial Cancer and Cervical Cancer, sponsored by University of Oklahoma.
- Completed
- Registry status
- Phase 2
- Development phase
- 49
- Enrollment target
- 3
- Study locations
NCT03476798: Completed Phase 2 study of Endometrial Cancer and Cervical Cancer, sponsored by University of Oklahoma.
NCT03476798 is a Phase 2 study of Endometrial Cancer and Cervical Cancer that has completed, run by University of Oklahoma. The registered enrollment target is 49 participants, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (91% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03476798, a Phase 2 study of Endometrial Cancer and Cervical Cancer, has completed, sponsored by University of Oklahoma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 49 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a phase II study of rucaparib, a small molecule inhibitor poly (adenosine diphosphate \[ADP\]-ribose) polymerase (PARP), being tested in combination with bevacizumab in patients with recurrent cervical or endometrial cancer. The objective of this study is to determine the proportion of these patients who survive progression-free for at least 6 months while receiving this drug combination.
Primary Outcome
To estimate the proportion of pts treated w/bevacizumab who are progression-free. Progression for measurable disease per RECIST v1.1. Progression for pts with non-measurable disease at baseline is defined as increasing clinical, radiological, or histological evidence of disease since study entry.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Rucaparib
Study Locations (3)
Minnesota
- University of Minnesota - Minneapolis
Oklahoma
- Stephenson Cancer Center, University of Oklahoma Health Sciences Center - Oklahoma City
Virginia
- University of Virginia Cancer Center - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2018-06-29 |
| Est. Completion | 2023-09-29 |
| Phase | Phase 2 |
What the finished NCT03476798 record still lists
NCT03476798 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (91% lower).
The record links to 2 conditions, with Endometrial Cancer appearing as the primary indexed condition, and to 2 interventions - of which Bevacizumab is the first listed.
NCT03476798 reports a single indexed study location in Minnesota, Oklahoma, Virginia.
Frequently Asked Questions
What is clinical trial NCT03476798 about?
NCT03476798 is a clinical study titled "Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium". This is a phase II study of rucaparib, a small molecule inhibitor poly (adenosine diphosphate \[ADP\]-ribose) polymerase (PARP), being tested in combination with bevacizumab in patients with recurrent cervical or endometrial cancer. The objective of this study is to determine the proportion of these...
What is the current status of trial NCT03476798?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2018-06-29. Estimated completion is 2023-09-29.
What conditions does trial NCT03476798 study?
This clinical trial studies the following conditions: Endometrial Cancer, Cervical Cancer.
What interventions are being tested in trial NCT03476798?
The interventions under investigation include: Bevacizumab (DRUG), Rucaparib (DRUG).
Who is sponsoring clinical trial NCT03476798?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03476798 being conducted?
This trial has 3 study locations across Minnesota, Oklahoma, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03476798's enrollment target sits among peer trials
49 129th of 181 higher than 53 of 181 other Endometrial Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Endometrial Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
RECRUITING · Phase 2
-
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
RECRUITING · Phase 2
-
Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery
RECRUITING · Phase 2
-
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
RECRUITING · Phase 2
-
Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer
RECRUITING · Phase 2
-
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI